Nasdaq17d
Oragenics, Inc. Submits Investigator's Brochure for Phase II Clinical Trial of ONP-002 in Australia for Mild Traumatic Brain Injury
no FDA-approved drug therapies currently exist, leaving a significant unmet medical need. “The submission of our Investigator’s Brochure application marks a critical step forward in advancing ...
Business Insider17d
Oragenics, Inc. Submits Investigator’s Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI)
no FDA-approved drug therapies currently exist, leaving a significant unmet medical need. “The submission of our Investigator’s Brochure application marks a critical step forward in advancing ...
Oragenics, Inc. Submits Investigator’s Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI)
Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for concussion and ...